<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39375884</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-3148</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Transfusion medicine (Oxford, England)</Title><ISOAbbreviation>Transfus Med</ISOAbbreviation></Journal><ArticleTitle>A safety comparison of heparin and argatroban anticoagulation in veno-venous extracorporeal membrane oxygenation with a focus on bleeding.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/tme.13102</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Anticoagulation during extracorporeal membrane oxygenation (ECMO) might still lead to severe bleeding complications. Heparin is the most frequently used anticoagulant, but novel drugs could be promising. Argatroban is a new alternative to heparin. To date, no robust studies have confirmed the clear superiority of argatroban (AG) over heparin, although it has some advantages and may be safer.</AbstractText><AbstractText Label="STUDY DESIGN AND METHODS" NlmCategory="METHODS">An observational study was conducted in all adult veno-venous ECMO patients with COVID-19-associated acute respiratory distress syndrome admitted to the University Hospital Ostrava (n = 63). They were anticoagulated with heparin in the first period and with AG in the second period, targeting the same activated partial thromboplastin time (aPTT; 45-60 s). Bleeding complications requiring transfusion and life-threatening bleeding events were evaluated. The primary objective was to compare heparin and AG in terms of bleeding, transfusion requirements and mortality-related bleeding.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The total time on ECMO per patient was 16 days with an in-hospital mortality of 55.6%. The red blood cell consumption in the AG group (median 2.7 transfusions/week) was significantly lower than in the heparin group (median 4.2 transfusions/week, p = 0.011). Life-threatening bleeding complications were higher in the heparin group compared to the AG group (35.7% vs. 10.2%, p = 0.035), and mortality-related bleeding complications were also higher in the heparin group (21.4% vs. 2.0%, p = 0.032).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Argatroban is an interesting alternative to heparin with less bleeding, less need for red blood cell transfusions and improved safety of ECMO with less mortality-related bleeding.</AbstractText><CopyrightInformation>© 2024 The Author(s). Transfusion Medicine published by John Wiley &amp; Sons Ltd on behalf of British Blood Transfusion Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burša</LastName><ForeName>Filip</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9770-1433</Identifier><AffiliationInfo><Affiliation>Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Máca</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagan</LastName><ForeName>Jiří</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sklienka</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Němcová</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kučerová</LastName><ForeName>Zuzana</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romanová</LastName><ForeName>Tereza</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jor</LastName><ForeName>Ondřej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondé</LastName><ForeName>Adéla</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics, Faculty of Electrical Engineering and Computer Science, VSB- Technical University of Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of the Deputy Director for Science, Research and Education, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janošek</LastName><ForeName>Jaroslav</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Health Research, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frelich</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FNOs/2024</GrantID><Agency>Ministerstvo Zdravotnictví Ceské Republiky</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transfus Med</MedlineTA><NlmUniqueID>9301182</NlmUniqueID><ISSNLinking>0958-7578</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anticoagulation</Keyword><Keyword MajorTopicYN="N">argatroban</Keyword><Keyword MajorTopicYN="N">bleeding</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation (ECMO)</Keyword><Keyword MajorTopicYN="N">heparin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39375884</ArticleId><ArticleId IdType="doi">10.1111/tme.13102</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Martucci G, Słomka A, Lebowitz SE, et al. COVID‐19 and extracorporeal membrane oxygenation. Adv Exp Med Biol. 2021;1353:173‐195. doi:10.1007/978‐3‐030‐85113‐2_10</Citation></Reference><Reference><Citation>Burša F, Frelich M, Sklienka P, Jor O, Máca J. Long‐term outcomes of extracorporeal life support in respiratory failure. J Clin Med. 2023;12(16):5196. doi:10.3390/JCM12165196</Citation></Reference><Reference><Citation>Pratt EH, Stokes JW, Fan E. Bleeding and clotting while supported with ECMO: time to move forward. Intensive Care Med. 2022;48(8):1059‐1061. doi:10.1007/S00134‐022‐06805‐Y</Citation></Reference><Reference><Citation>Nunez JI, Gosling AF, O'Gara B, et al. Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis. Intensive Care Med. 2022;48(2):213‐224. doi:10.1007/S00134‐021‐06593‐X</Citation></Reference><Reference><Citation>Lv X, Deng M, Wang L, Dong Y, Chen L, Dai X. Low vs standardized dose anticoagulation regimens for extracorporeal membrane oxygenation: a meta‐analysis. PLoS One. 2021;16(4):e0249854. doi:10.1371/JOURNAL.PONE.0249854</Citation></Reference><Reference><Citation>Martucci G, Giani M, Schmidt M, et al. Anticoagulation and bleeding during Veno‐venous extracorporeal membrane oxygenation: insights from the PROTECMO study. Am J Respir Crit Care Med. 2024;209(4):417‐426. doi:10.1164/RCCM.202305‐0896OC</Citation></Reference><Reference><Citation>Burša F, Sklienka P, Frelich M, Jor O, Ekrtová T, Máca J. Anticoagulation management during extracorporeal membrane oxygenation‐a mini‐review. Medicina (Kaunas). 2022;58(12):1783. doi:10.3390/MEDICINA58121783</Citation></Reference><Reference><Citation>Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526‐2533. doi:10.1001/JAMA.2012.5669</Citation></Reference><Reference><Citation>Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID‐19: an international cohort study of the extracorporeal life support organization registry. The Lancet. 2020;396(10257):1071‐1078. doi:10.1016/S0140‐6736(20)32008‐0</Citation></Reference><Reference><Citation>Ramanathan K, Shekar K, Ling RR, et al. Extracorporeal membrane oxygenation for COVID‐19: a systematic review and meta‐analysis. Crit Care. 2021;25(1):1‐11. doi:10.1186/S13054‐021‐03634‐1/TABLES/3</Citation></Reference><Reference><Citation>Capila I, Linhardt RJ. Heparin‐protein interactions. Angew Chem Int Ed Engl. 2002;41(3):390‐412. doi:10.1002/1521‐3773(20020201)41:3&lt;390::aid‐anie390&gt;3.0.co;2‐b</Citation></Reference><Reference><Citation>Binari RC, Staveley BE, Johnson WA, Godavarti R, Sasisekharan R, Manoukian AS. Genetic evidence that heparin‐like glycosaminoglycans are involved in wingless signaling. Development. 1997;124(13):2623‐2632. doi:10.1242/DEV.124.13.2623</Citation></Reference><Reference><Citation>Castelli R, Porro F, Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med. 2004;9(3):205‐213. doi:10.1191/1358863X04VM566RA</Citation></Reference><Reference><Citation>Levy JH, Connors JM. Heparin resistance—clinical perspectives and management strategies. N Engl J Med. 2021;385(9):826‐832. doi:10.1056/NEJMRA2104091/SUPPL_FILE/NEJMRA2104091_DISCLOSURES.PDF</Citation></Reference><Reference><Citation>Hileman BA, Martucci G, Rizzitello N, et al. Antithrombin during veno‐venous extracorporeal membrane oxygenation with heparin anticoagulation: a single‐center cohort study. Perfusion. 2024;4:2676591241258048. doi:10.1177/02676591241258048</Citation></Reference><Reference><Citation>Godier A, Clausse D, Meslin S, et al. Major bleeding complications in critically ill patients with COVID‐19 pneumonia. J Thromb Thrombolysis. 2021;52:18‐21. doi:10.1007/s11239‐021‐02403‐9</Citation></Reference><Reference><Citation>Lee GM, Arepally GM. Heparin‐induced thrombocytopenia. Hematology. 2013;2013(1):668‐674. doi:10.1182/ASHEDUCATION‐2013.1.668</Citation></Reference><Reference><Citation>Choi JH, Luc JGY, Weber MP, et al. Heparin‐induced thrombocytopenia during extracorporeal life support: incidence, management and outcomes. Ann Cardiothorac Surg. 2019;8(1):19‐31. doi:10.21037/ACS.2018.12.02</Citation></Reference><Reference><Citation>Ito M, Baba M, Sato A, Pauwels R, de Clercq E, Shigeta S. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res. 1987;7(6):361‐367. doi:10.1016/0166‐3542(87)90018‐0</Citation></Reference><Reference><Citation>Mycroft‐West C, Su D, Elli S, et al. The 2019 coronavirus (SARS‐CoV‐2) surface protein (spike) S1 receptor binding domain undergoes conformational change upon heparin binding. bioRxiv. 2020;971093. doi:10.1101/2020.02.29.971093</Citation></Reference><Reference><Citation>Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72(4):581‐592. doi:10.1111/J.1365‐2125.2011.03916.X</Citation></Reference><Reference><Citation>Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol. 2000. https://pubmed.ncbi.nlm.nih.gov/11156731/;12 Suppl F:27F‐232F.</Citation></Reference><Reference><Citation>Rougé A, Pelen F, Durand M, Schwebel C. Argatroban for an alternative anticoagulant in HIT during ECMO. J Intensive Care. 2017;5(1):1‐5. doi:10.1186/S40560‐017‐0235‐Y</Citation></Reference><Reference><Citation>Walenga JM. An overview of the direct thrombin inhibitor Argatroban. Pathophysiol Haemost Thromb. 2002;32(Suppl. 3):9‐14. doi:10.1159/000069103</Citation></Reference><Reference><Citation>Dolch MEFLHR et al. Extracorporeal membrane oxygenation bridging to lung transplant complicated by heparin‐induced thrombocytopenia. Exp Clin Transplant. 2010;8(4):329‐332.</Citation></Reference><Reference><Citation>Patel K, Saraf P, Shiu D, et al. Safety profile of Argatroban vs heparin for anticoagulation in patients requiring extra corporeal membrane oxygenation (ECMO) therapy. Chest. 2015;148(4):193A. doi:10.1378/CHEST.2281355</Citation></Reference><Reference><Citation>Iba T, Levy JH, Maier CL, Connors JM, Levi M. Four years into the pandemic, managing COVID‐19 patients with acute coagulopathy: what have we learned? J Thromb Haemost. 2024;22(6):1541‐1549. doi:10.1016/J.JTHA.2024.02.013</Citation></Reference><Reference><Citation>Manzur‐Pineda K, O'Neil CF, Bornak A, et al. COVID‐19‐related thrombotic complications experience before and during delta wave. J Vasc Surg. 2022;76(5):1374‐1382.e1. doi:10.1016/J.JVS.2022.04.053</Citation></Reference><Reference><Citation>Mcmichael ABV, Ryerson LM, Ratano D, et al. ELSO adult and pediatric anticoagulation guidelines. ASAIO J. 2021;2022:303‐310. doi:10.1097/MAT.0000000000001652</Citation></Reference><Reference><Citation>Rad F, Dabbagh A, Dorgalaleh A, Biswas A. The relationship between inflammatory cytokines and coagulopathy in patients with COVID‐19. J Clin Med. 2021;10(9):2020. doi:10.3390/jcm10092020</Citation></Reference><Reference><Citation>Fisser C, Winkler M, Malfertheiner MV, et al. Argatroban versus heparin in patients without heparin‐induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity‐score matched study. Crit Care. 2021;25(1):160. doi:10.1186/S13054‐021‐03581‐X</Citation></Reference><Reference><Citation>Cho AE, Jerguson K, Peterson J, Patel DV, Saberi AA. Cost‐effectiveness of Argatroban versus heparin anticoagulation in adult extracorporeal membrane oxygenation patients. Hosp Pharm. 2021;56(4):276‐281. doi:10.1177/0018578719890091</Citation></Reference><Reference><Citation>Sattler LA, Boster JM, Ivins‐O'keefe KM, et al. Argatroban for anticoagulation in patients requiring Venovenous extracorporeal membrane oxygenation in coronavirus disease 2019. Crit Care Explor. 2021;3(9):e0530. doi:10.1097/CCE.0000000000000530</Citation></Reference><Reference><Citation>Stammers AH, Tesdahl EA, Barletti S, et al. Anticoagulant use during extracorporeal membrane oxygenation using heparin and direct thrombin inhibitors in COVID‐19 and ARDS patients. J Extra Corpor Technol. 2022;54(3):223‐234. doi:10.1182/JECT‐223‐234</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>